Cargando…
A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
Autores principales: | Kow, Chia Siang, Hasan, Syed Shahzad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834767/ https://www.ncbi.nlm.nih.gov/pubmed/33423787 http://dx.doi.org/10.1016/j.therap.2020.12.015 |
Ejemplares similares
-
Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020) -
Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis
por: Kow, Chia Siang, et al.
Publicado: (2021) -
The impact of preadmission/prediagnosis use of GLP‐1 receptor agonists on COVID‐19 mortality in patients with diabetes: A systematic review and meta‐analysis
por: Kow, Chia Siang, et al.
Publicado: (2023) -
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis
por: Kow, Chia Siang, et al.
Publicado: (2021) -
Combination Therapy with CCBs and RAS Inhibitors to Counteract Endothelial Dysfunction in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2022)